Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

FDA approves Xarelto to reduce risk of major CV events in coronary or peripheral artery disease

Oct. 15, 2018

Cardio Therapeutics patent describes PCSK9 inhibitors

Oct. 11, 2018

Cancer drugs may be repurposed for inflammation

Oct. 10, 2018

UMC Utrecht Holding synthesizes modified serpins for bradykinin-mediated diseases

Oct. 8, 2018

Palobiofarma presents adenosine A1 receptor antagonists

Oct. 3, 2018

HGPS and the heart

Oct. 2, 2018

NEAT1 found as new therapeutic target for occlusive vascular diseases

Oct. 1, 2018

CHK1 inhibition improves established PAH in vivo

Sep. 26, 2018

EZH2 as a novel biomarker in pulmonary arterial hypertension

Sep. 26, 2018

IL-34 protects mice from lethal sepsis

Sep. 26, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.